↓ Skip to main content

Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial

Overview of attention for article published in Trials, December 2015
Altmetric Badge

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
115 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial
Published in
Trials, December 2015
DOI 10.1186/s13063-015-1102-6
Pubmed ID
Authors

Selma Tülü, Miriam Mulino, Daniel Pinggera, Markus Luger, Philipp Würtinger, Astrid Grams, Thomas Bodner, Ronny Beer, Raimund Helbok, Raffaella Matteucci-Gothe, Claudia Unterhofer, Elke Gizewski, Erich Schmutzhard, Claudius Thomé, Martin Ortler

Abstract

The treatment of intracranial aneurysms may be associated with cerebral ischemia. We hypothesize that pre-interventional remote ischemic preconditioning (RIPC) reduces ischemic cerebral tissue damage in patients undergoing elective intracranial aneurysm treatment. This study is a single-center, prospective, randomized, double-blind explorative trial. Patients with an unruptured intracranial aneurysm admitted to Innsbruck Medical University Hospital for coiling or clipping will be consecutively randomized to either the intervention group (= RIPC by inflating an upper extremity blood-pressure cuff for 3 x 5 min to 200 mmHg) or the control group after induction of anesthesia. Participants will be randomized 1:1 to either the preconditioning group or the sham group using a random allocation sequence and block randomization. The precalculated sample size is n = 24 per group. The primary endpoint is the area-under-the-curve concentration of serum biomarkers (S100B, NSE, GFAP, MMP9, MBP, and cellular microparticles) in the first five days after treatment. Secondary endpoints are the number and volume of new ischemic lesions in magnetic resonance imaging and clinical outcome evaluated with the National Institutes of Health Stroke Scale, the modified Rankin Scale, and neuropsychological tests at six and twelve months. All outcome variables will be determined by observers blinded to group allocation. This study was approved by the local institutional Ethics Committee (UN5164), version 3.0 of the study protocol, dated 20 October 2013. This study uses the elective treatment of intracranial aneurysms as a paradigmatic situation to explore the neuroprotective effects of RIPC. If effects are demonstrable in this pilot trial, a larger, prospective phase III trial will be considered.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 115 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 14%
Student > Master 12 10%
Researcher 11 10%
Student > Ph. D. Student 9 8%
Other 8 7%
Other 22 19%
Unknown 37 32%
Readers by discipline Count As %
Medicine and Dentistry 38 33%
Neuroscience 6 5%
Agricultural and Biological Sciences 6 5%
Nursing and Health Professions 4 3%
Psychology 3 3%
Other 9 8%
Unknown 49 43%